Patents by Inventor Bronislava Gedulin

Bronislava Gedulin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE
    Publication number: 20230212211
    Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 23, 2022
    Publication date: July 6, 2023
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
  • BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
    Publication number: 20220362238
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Application
    Filed: January 13, 2022
    Publication date: November 17, 2022
    Inventors: Bronislava GEDULIN, Andrew A. YOUNG, Howard E. GREENE
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20220265649
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 27, 2022
    Publication date: August 25, 2022
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Bronislava GEDULIN, Michael Grey, Niall O'DONNELL
  • Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
    Patent number: 11376251
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: July 5, 2022
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
  • Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
    Patent number: 11260053
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: March 1, 2022
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20220023296
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 27, 2022
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Bronislava GEDULIN, Michael Grey, Niall O'DONNELL
  • Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
    Patent number: 11229661
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: January 25, 2022
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20200246366
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 11, 2019
    Publication date: August 6, 2020
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE
    Publication number: 20200207797
    Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 26, 2019
    Publication date: July 2, 2020
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20200069715
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 5, 2020
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava GEDULIN, Michael Grey, Niall O'Donnell
  • Bile acid recycling inhibitors for treatment of obesity and diabetes
    Patent number: 10555950
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 11, 2020
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
    Patent number: 10512657
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 24, 2019
    Assignee: LUMENA PHARMACEUTIALS LLC
    Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
  • BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
    Publication number: 20190247390
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 15, 2019
    Inventors: Bronislava GEDULIN, Andrew A. YOUNG, Howard E. GREENE
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE
    Publication number: 20190169217
    Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 6, 2019
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava GEDULIN, Michael GREY, Niall O'DONNELL
  • Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
    Patent number: 10251880
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 9, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
    Patent number: 10188646
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 29, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
    Patent number: 10028952
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 24, 2018
    Assignee: SATIOGEN PHARMACEUTICALS, INC
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20170368085
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES
    Publication number: 20160310518
    Abstract: Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 25, 2016
    Publication date: October 27, 2016
    Applicant: Lumena Pharmaceuticals LLC
    Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
  • METHODS OF TREATING DIABETES OR OBESITY USING BILE ACIDS, BILE SALTS, AND MIMICS THEREOF
    Publication number: 20160235745
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene